Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Sunitinib is an oral targeted therapy approved to treat cancer of the stomach and pancreas, so it is easily available. The 6 month progression free survival rate was 42%, which is much better than anything I have seen for this type of tumor. The overall survival rates are still not good enough but perhaps this may become another tool to use as part of a comprehensive treatment plan that does much better.
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://neuro-oncology.oxfordjournals.org/content/early/2014/08/05/neuonc.nou148.abstract
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines